Beth Toste Harrison, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 4 | 2022 | 484 | 1.020 |
Why?
|
| Breast Neoplasms | 14 | 2022 | 20822 | 0.980 |
Why?
|
| Inflammatory Breast Neoplasms | 4 | 2023 | 143 | 0.730 |
Why?
|
| Receptor, erbB-3 | 1 | 2020 | 142 | 0.670 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2019 | 200 | 0.660 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 210 | 0.620 |
Why?
|
| Gene Fusion | 1 | 2019 | 371 | 0.570 |
Why?
|
| Receptor, erbB-2 | 3 | 2022 | 2416 | 0.560 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 155 | 0.520 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 949 | 0.520 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 368 | 0.520 |
Why?
|
| Broad Ligament | 1 | 2014 | 5 | 0.500 |
Why?
|
| Peritoneum | 1 | 2015 | 228 | 0.490 |
Why?
|
| Fibroma | 1 | 2016 | 212 | 0.490 |
Why?
|
| Immunohistochemistry | 6 | 2020 | 11366 | 0.480 |
Why?
|
| Carcinoma | 4 | 2020 | 2375 | 0.470 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 506 | 0.460 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2018 | 709 | 0.460 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1101 | 0.460 |
Why?
|
| Adnexal Diseases | 1 | 2014 | 102 | 0.450 |
Why?
|
| Pleural Effusion | 1 | 2016 | 338 | 0.440 |
Why?
|
| Ovarian Diseases | 1 | 2014 | 139 | 0.440 |
Why?
|
| Breast | 3 | 2023 | 1969 | 0.430 |
Why?
|
| Edema | 1 | 2014 | 789 | 0.360 |
Why?
|
| Endometrial Neoplasms | 4 | 2020 | 1353 | 0.350 |
Why?
|
| Leiomyoma | 1 | 2014 | 730 | 0.330 |
Why?
|
| Medical Errors | 1 | 2016 | 1297 | 0.320 |
Why?
|
| Axilla | 2 | 2022 | 595 | 0.310 |
Why?
|
| Patient Selection | 2 | 2020 | 4215 | 0.310 |
Why?
|
| Endometriosis | 1 | 2015 | 839 | 0.300 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2020 | 271 | 0.280 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 2212 | 0.270 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 1363 | 0.250 |
Why?
|
| Lymphatic Metastasis | 3 | 2022 | 2924 | 0.240 |
Why?
|
| Paget Disease, Extramammary | 1 | 2023 | 45 | 0.220 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2023 | 808 | 0.200 |
Why?
|
| Keratins | 1 | 2022 | 515 | 0.190 |
Why?
|
| Paris | 1 | 2019 | 42 | 0.180 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 345 | 0.180 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 4838 | 0.170 |
Why?
|
| DNA Copy Number Variations | 3 | 2023 | 1941 | 0.170 |
Why?
|
| Female | 26 | 2023 | 380194 | 0.170 |
Why?
|
| Mucins | 1 | 2022 | 564 | 0.160 |
Why?
|
| Body Surface Area | 1 | 2009 | 198 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 318 | 0.160 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 198 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 890 | 0.150 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2018 | 91 | 0.150 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 107 | 0.150 |
Why?
|
| 14-3-3 Proteins | 1 | 2018 | 214 | 0.150 |
Why?
|
| Cadherins | 1 | 2022 | 907 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 2649 | 0.140 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 806 | 0.140 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 349 | 0.140 |
Why?
|
| Gene Amplification | 1 | 2020 | 1063 | 0.140 |
Why?
|
| Nipples | 1 | 2018 | 219 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2023 | 2245 | 0.130 |
Why?
|
| Necrosis | 1 | 2019 | 1643 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2019 | 492 | 0.120 |
Why?
|
| Uterine Hemorrhage | 1 | 2016 | 255 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 12959 | 0.120 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 435 | 0.120 |
Why?
|
| Humans | 28 | 2023 | 744343 | 0.120 |
Why?
|
| Genital Neoplasms, Female | 1 | 2009 | 523 | 0.110 |
Why?
|
| Mucin-1 | 1 | 2017 | 543 | 0.110 |
Why?
|
| Repressor Proteins | 2 | 2023 | 3023 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1641 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1261 | 0.100 |
Why?
|
| Pelvis | 1 | 2016 | 730 | 0.100 |
Why?
|
| Middle Aged | 12 | 2022 | 213383 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2022 | 3474 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2703 | 0.090 |
Why?
|
| Syndrome | 1 | 2016 | 3251 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15076 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 9239 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2014 | 927 | 0.080 |
Why?
|
| Biopsy | 2 | 2021 | 6756 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3597 | 0.080 |
Why?
|
| Adult | 9 | 2022 | 214055 | 0.080 |
Why?
|
| DNA | 1 | 2022 | 7301 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2948 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 19905 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 13695 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2021 | 77449 | 0.070 |
Why?
|
| Polyglutamic Acid | 1 | 2005 | 44 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 57776 | 0.070 |
Why?
|
| Guided Tissue Regeneration | 1 | 2005 | 85 | 0.060 |
Why?
|
| Aged | 7 | 2022 | 163280 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5510 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2020 | 6544 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9438 | 0.060 |
Why?
|
| Neurites | 1 | 2005 | 388 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2016 | 5985 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 7913 | 0.050 |
Why?
|
| Pyrroles | 1 | 2005 | 1146 | 0.040 |
Why?
|
| Mammography | 2 | 2021 | 2476 | 0.040 |
Why?
|
| Hormones | 1 | 2022 | 889 | 0.040 |
Why?
|
| Polymers | 1 | 2005 | 1621 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 1185 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 4851 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 35421 | 0.040 |
Why?
|
| Nausea | 1 | 2009 | 673 | 0.030 |
Why?
|
| Carboplatin | 1 | 2009 | 801 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2020 | 1252 | 0.030 |
Why?
|
| Prognosis | 3 | 2022 | 29063 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2022 | 901 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 426 | 0.030 |
Why?
|
| North America | 1 | 2018 | 1249 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 2187 | 0.030 |
Why?
|
| Kinetics | 1 | 2021 | 6473 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 1850 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 56430 | 0.030 |
Why?
|
| Mastectomy | 1 | 2021 | 1793 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 1179 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2749 | 0.030 |
Why?
|
| United States | 1 | 2019 | 69872 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 63114 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2009 | 1708 | 0.030 |
Why?
|
| Adolescent | 1 | 2019 | 85781 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 1616 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3339 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 1179 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 1375 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3616 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4186 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8642 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 3913 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 10252 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 2942 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 4669 | 0.020 |
Why?
|
| Male | 3 | 2023 | 350118 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 12245 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 12354 | 0.020 |
Why?
|
| Cell Enlargement | 1 | 2005 | 61 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2005 | 114 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2005 | 145 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
| Polylysine | 1 | 2005 | 133 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 11031 | 0.020 |
Why?
|
| Mutation | 2 | 2020 | 29786 | 0.020 |
Why?
|
| Laminin | 1 | 2005 | 419 | 0.010 |
Why?
|
| Neurofilament Proteins | 1 | 2005 | 318 | 0.010 |
Why?
|
| Ganglia, Spinal | 1 | 2005 | 519 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2009 | 12720 | 0.010 |
Why?
|
| Cell Count | 1 | 2005 | 1856 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 16689 | 0.010 |
Why?
|
| Nerve Regeneration | 1 | 2005 | 788 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 11524 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 18029 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39050 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 40075 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 40561 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2020 | 53288 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13102 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 72290 | 0.010 |
Why?
|
| Animals | 2 | 2016 | 168757 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 81183 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 24260 | 0.010 |
Why?
|
| Neurons | 1 | 2005 | 9338 | 0.000 |
Why?
|